EC approves Bristol Myers’ anti-BCMA CAR T-cell treatment for multiple myeloma

The approval is based on data from the pivotal KarMMa trial which enrolled 128 relapsed and refractory multiple myeloma patients. Credit: Angelo Esslinger from Pixabay.